A REAL-WORLD (RW) COMPARISON OF HEALTHCARE EXPENDITURES IN PATIENTS PRESCRIBED ARIPIPRAZOLE TABLET WITH SENSOR (AS) AND PATIENTS PRESCRIBED ARIPIPRAZOLE ALONE [ARIPIPRAZOLE WITHOUT SENSOR (ARI)] IN THE US

Indicated for treatment of adults with bipolar I disorder (BP1), schizophrenia (SCZ) and major depressive disorder (MDD), AS is a drug-device system comprised of aripiprazole tablets embedded with an Ingestible Event Marker tracking drug ingestion, mood, rest and physical activity. This study compares healthcare expenditures in patients prescribed AS versus a matched ari only cohort.